Results 31 to 40 of about 645 (124)

Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. [PDF]

, 2017
BACKGROUND: The emergence of programmatically incurable tuberculosis threatens to destabilise control efforts. The aim of this study was to collect prospective patient-level data to inform treatment and containment strategies.
Abdallah, Abdallah M, Ben-Rached, Fathia, Clark, Taane G, Dheda, Keertan, Dolby, Tania, Esmail, Aliasgar, Fennelly, Kevin P, Gumbo, Tawanda, Lesosky, Maia, Limberis, Jason D, Mastrapa, Barbara, McNerney, Ruth, Pain, Arnab, Phelan, Jody, Pietersen, Elize, Simpson, John, Sirgel, Frederick A, Smith, Liezel, Streicher, Elizabeth M, Te Riele, Julian, Theron, Grant, van Helden, Paul, Warren, Robin M   +22 more
core   +1 more source

Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay [PDF]

, 2013
Objectives: Lead antituberculosis (anti-TB) molecules with novel mechanisms of action are urgently required to fuel the anti-TB drug discovery pipeline.
Bhakta, Sanjib, Birchall, K., Evangelopoulos, Dimitrios, Gibbons, S., Gupta, Antima, Guzman, Juan D., Malkinson, J., McHugh, T.D., Mwaigwisya, S., Saxty, B.   +9 more
core   +1 more source

Treatment-shortening regimens for tuberculosis: updates and future priorities [PDF]

, 2023
In the past 2 years, remarkable advances have been made in shortening tuberculosis (TB) treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB-PRACTECAL) have provided evidence of the efficacy of regimens based on new and ...
Adepoju, VA, Duarte, R, Lange, C, Phillips, PPJ, Saluzzo, F   +4 more
core   +2 more sources

Assessment of treatment response in tuberculosis [PDF]

, 2016
Antibiotic treatment of tuberculosis has a duration of several months. There is significant variability of the host immune response and the pharmacokinetic-pharmacodynamic properties of Mycobacterium tuberculosis sub-populations at the site of disease. A
Du Bruyn, E, Morris, T, Rockwood, N, Wilkinson, RJ   +3 more
core   +1 more source

Application of metabolomics to drug discovery and understanding the mechanisms of action of medicinal plants with anti‐tuberculosis activity

Clinical and Translational Medicine, Volume 7, Issue 1, December 2018., 2018
AbstractHuman tuberculosis (TB) is amongst the oldest and deadliest human bacterial diseases that pose major health, social and economic burden at a global level. Current regimens for TB treatment are lengthy, expensive and ineffective to emerging drug resistant strains. Thus, there is an urgent need for identification and development of novel TB drugs
Naasson Tuyiringire, Deusdedit Tusubira, Jean‐Pierre Munyampundu, Casim Umba Tolo, Claude M. Muvunyi, Patrick Engeu Ogwang   +5 more
wiley   +1 more source

TB and HIV Therapeutics: Pharmacology Research Priorities

AIDS Research and Treatment, Volume 2012, Issue 1, 2012., 2012
An unprecedented number of investigational drugs are in the development pipeline for the treatment of tuberculosis. Among patients with tuberculosis, co‐infection with HIV is common, and concurrent treatment of tuberculosis and HIV is now the standard of care.
Kelly E. Dooley, Peter S. Kim, Sharon D. Williams, Richard Hafner, Gary Maartens   +4 more
wiley   +1 more source

Antimicrobial peptides as novel anti-tuberculosis therapeutics [PDF]

, 2016
"Available online 24 May 2016"Tuberculosis (TB), a disease caused by the human pathogen Mycobacterium tuberculosis, has recently joined HIV/AIDS as the world's deadliest infectious disease, affecting around 9.6 million people worldwide in 2014. Of those,
Agerberth, Ahsan, Andersson, Andersson, Andries, Aoki, Asaduzzaman, Balasubramanian, Bartolomeo, Bauer, Bayer, Bell, Bierbaum, Blaas, Bogatcheva, Bottger, Bray, Brogden, Brown, Brötz, Butler, Carroll, Center for Drug Evaluation and Research (CDER), Cervantes-Villagrana, Champion, Champion, Ciornei, Cohen, Corrales-Garcia, Courvalin, Diel, Directorate-General of the European Comission, Duplantier, Durr, Eckert, Ernst, European Commission, European Commission, European Commission, European Medicines Agency, Fattorini, Florence, Food and Drug Administration (FDA), Food and Drug Administration (FDA), Fox, Fox, Fox, Francisco Miguel Gama, Fratti, Fuertes, Gaspar, Gelperina, Ghobrial, Giehl, Giuliani, Gler, Global Alliance for TB Drug Development, Global Drug Facility, Goldstein, Gottler, Guirado, Gunther, Hancock, Hancock, Harper, Harris, Hmama, Horn, Hunter, International Conference on Harmonizarion Expert Working Group, Ishizaki, Islam, Jarlier, Jena, Jiang, Jin, João P. Silva, Kalita, Kaplan, Kapoor, Kaspar, Kayser, Khara, Kik, Kisich, Kusnadi, Kwok, Lan, Lax, Lax, Lee, Lee, Lehrer, Levy, Li, Li, Li, Limoli, Linde, Lunov, Makarov, Mansour, Mariappan, Marr, Matsuzaki, Matsuzaki, McGhan, Miller-Keane, Mily, Miteva, Mohanty, Molhoek, Mukherjee, Mygind, Médecins sans Frontières (MSF), Nagaoka, Nawrocki, Neyrolles, Nikonenko, Nizet, Nizet, Onyebujoh, Oren, Orme, Otvos, Padhi, Pandey, Pandey, Park, Patrzykat, Peschel, Peschel, Pethe, Pietiainen, Pokorny, Prideaux, Protopopova, Ramon-Garcia, Ramos, Ramos, Rathinakumar, Rivas-Santiago, Rivas-Santiago, Rivas-Santiago, Rosenfeld, Roy, Rubinchik, Rui Appelberg, Rutherfurd, Sanborn, Santos, Santos, Saravolatz, Schatz, Scheinpflug, Sensi, Shai, Shai, Sharma, Sharma, Shaw, Sherman, Shinnar, Silva, Somoskovi, Sosnik, Sosunov, Stehr, Steinstraesser, Stenger, Sterling, Sundararajan, Swietlow, Tabata, Tahlan, Tasneen, Tomioka, Toro, Torres-Juarez, Transparency Market Research, Uhlig, van der Does, Vilcheze, Vlieghe, Wallis, Wang, Wang, Welsh, Wenzel, Wiedemann, Wimley, World Health Organization, World Health Organization (WHO), World Health Organization (WHO), World Health Organization (WHO), World Health Organization (WHO), Xiong, Yamasaki, Yang, Yeaman, Zasloff, Zasloff, Zeitler, Zelezetsky, Zhang, Zhao, Zumla, Zumla, Zumla   +208 more
core   +1 more source

Challenges and recent progress in drug discovery for tropical diseases [PDF]

, 2018
Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries. These diseases predominantly affect the world’s poorest people.
A Guidi, A Hoerauf, AF Francisco, AK Kakkar, AK Njamnshi, AN Cowell, B Amadi, B Baragana, B Blasco, B Wahid, Beatriz Baragaña, CA Fux, CD Huston, CE Barry III, CE Coltart, D Sissoko, DA Lamprecht, DG Brown, DI Stanisic, DM Plouffe, DS Shepard, DT Hoagland, E Bushell, E Chatelain, E Chatelain, E Check Hayden, E Tacconelli, E Torreele, E Wit de, F Josephson, F Macintyre, FJ Sanchez-Valdez, FX Blanc, G Priotto, G-Finder, H Myllymaki, Hotez, I Angulo-Barturen, I Kramnik, I Molina, Ian H. Gilbert, ID Olaru, IPFMA, J Keiser, J Liu, J Whitehorn, JG Kublin, JN Burrows, JP Sarathy, JR Perfect, JS McCarthy, JS McCarthy, K Awadzi, K Basile, KH Mayer, KK Irwin, KL Kotloff, L Conteh, LJ Zhan, LL Silver, M Lee, M Matsumoto, MA Hulverson, Manu De Rycker, MB Jimenez-Diaz, MC Field, MC Pawlowic, MF Fromm, ML Ang, ML Hovlid, MS Love, MY Lim, N Ford, N Gyawali, N Lander, N Woodford, NA Meanwell, NJ White, NJ White, NJ White, NR Mansour, OP Singh, P Buscher, P Horvath, P Steinmann, PG Wyatt, PJ Hotez, R Rajasingham, R Taylor, RT Jacobs, S Baker, S Brooker, S Khare, S Sayasone, SA Mikolajczak, SD Pion, SH Xiao, SM Hammer, Suzanne L. Duce, T Paquet, TF Koning-Ward de, TK Warren, TN Wells, U Klarmann-Schulz, UH Manjunatha, UH Manjunatha, V Boldescu, V Mesu, VK Wong, W Checkley, W Moser, W Moser, W Zheng, Warren, World Health Organization, X Li, Y Debing, Y Wang   +117 more
core   +2 more sources

Population Pharmacokinetic/Pharmacodynamic Analysis of the Bactericidal Activities of Sutezolid (PNU-100480) and Its Major Metabolite against Intracellular Mycobacterium tuberculosis in Ex Vivo Whole-Blood Cultures of Patients with Pulmonary Tuberculosis [PDF]

Antimicrobial Agents and Chemotherapy, 2014
ABSTRACT Sutezolid (PNU-100480 [U-480]) is an oxazolidinone antimicrobial being developed for the treatment of tuberculosis. An active sulfoxide metabolite (PNU-101603 [U-603]), which reaches concentrations in plasma several times those of the parent, has been reported to drive the killing of extracellular ...
Tong Zhu, Sven O. Friedrich, Andreas Diacon, Robert S. Wallis   +3 more
openaire   +1 more source

Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis

Disease Models & Mechanisms, 2015
Mice are the most commonly used species for non-clinical evaluations of drug efficacy against tuberculosis (TB). Unlike commonly used strains, C3HeB/FeJ mice develop caseous necrosis in the lung, which might alter the representation of drug efficacy in a
Jean-Philippe Lanoix, Anne J. Lenaerts, Eric L. Nuermberger   +2 more
doaj   +1 more source